ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
February 23 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the
Company's fourth quarter and full year 2020 financial results will
be released after market close on Monday, March 1, 2021.
ChemoCentryx executive management will host a conference call and
webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to
discuss these results and to answer questions.
To participate by telephone, please dial (877) 303-8028
(Domestic) or (760) 536-5167 (International). The conference ID
number is 8283128. A live and archived audio webcast can be
accessed through the Investors section of the Company's website at
www.ChemoCentryx.com. The archived webcast will remain available on
the Company's website for fourteen (14) days following the
call.
About ChemoCentryx ChemoCentryx is a
biopharmaceutical company developing new medications for
inflammatory and autoimmune diseases and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late-stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).
ChemoCentryx also has early-stage drug candidates that target
chemoattractant receptors in other inflammatory and autoimmune
diseases and in cancer.
Contacts:
Susan M. KanayaExecutive Vice President,Chief
Financial and Administrative
Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Lee Roth, Burns McClellan212.213.0006
lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024